Jim Cramer's Duopoly Call: Why CME and Cboe Still Look Like Quiet Compounders

Cramer's duopoly point still stands for CME and Cboe

Cramer was right on the core point on August 5: CME and Cboe operate in a part of the market where scale and marketplace dynamics can support pricing power. CME already facilitates 92 percent of U.S. exchange-traded derivatives volumes by some measures, while Cboe has already shown how quickly volatility-driven activity can lift results. That is why the thesis still matters: investors are looking at platform franchises with durable trading, data, and clearing economics rather than ordinary commodity brokers.

The bull case and the regulatory pushback

The bull case is straightforward: exchanges earn revenue because trading happens, not because they guess which way the market moves. The pushback is also easy to understand. Critics are already asking regulators to look more closely at CME's near-monopoly in derivatives markets and at the competitive effects of any possible merger between CME and Cboe. So the real task for investors is not to worship the moat, but to decide whether the cash-generation story still works at today's expectations.

Why the exchange model works like a toll road

The appeal here is simpler than the "duopoly" label. When a trader futures a rate move, hedges an equity index, or buys a volatility product, the exchange is not betting on the direction of the trade. It gets paid because the trade clears on its platform. CME sits in a strong position across futures and options trading in major asset classes, while Cboe has shown how volatility demand can translate into stronger operating performance after its 27.8% July gain. If uncertainty keeps driving activity, the model remains powerful: small fees on large notional flows can build durable revenue.

What the market is already pricing in

These are not invisible businesses. The exchange model is clean because it sells access, data, and clearing rather than physical inventory, which helps explain the quality premium investors often assign to the sector. But that also means the market is not starting from zero. It already understands the appeal, so ownership only works if growth, margins, and capital allocation still have room to compound.

The only real threat to the model is structural, not cyclical. Critics are focused on CME's existing concentration of power and on whether the sector needs a broader regulatory review. If policy or antitrust action changes pricing, product design, or consolidation expectations, the multiple could reset even if the underlying business remains strong.

Valuation and positioning matter more than the narrative

The moat can be right while the stock still underperforms if valuation already prices in most of the good news. After that August 5 endorsement, the question is no longer whether CME and Cboe matter. It is whether each name still offers enough earnings runway at today's price to reward new buyers.

What to watch from here

• CME: Whether its broad footprint across asset classes continues to support steadier volume and clearing growth.
• Cboe: Whether performance becomes less tied to volatility spikes and more tied to durable options demand.
• Policy risk: Whether scrutiny of CME's existing concentration of power stays rhetorical or starts affecting industry expectations.
• Valuation discipline: Whether either franchise can grow into its multiple rather than depend on another rerating.

The cleaner setup

On balance, this still looks like a selective ownership story. CME appears better positioned for investors who want a steadier toll-road compounder. Cboe still offers more upside potential, but that case depends more on proving that demand can outlast the volatility cycle. For now, the best approach is not skepticism for its own sake. It is respecting the moat while demanding that the stock math still works.